New treatment options for patients with advanced BRCA-related breast cancer

Via Top Health News -- ScienceDaily

Six years ago an international team of physician scientists led a charge to advance clinical testing of the PARP inhibitor olaparib in cancer patients with known inherited BRCA mutations. This weekend, that push comes full circle with the presentation of results of the phase III OlympiAD trial demonstrating for the first time that olaparib is superior to chemotherapy in patients with BRCA-related advanced breast cancer.

View original post here:

%d bloggers like this: